Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Non-Small Cell Lung Cancer Metastatic 1Neurofibrosarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 15Doxorubicin 8Docetaxel 8Radiotherapy 7Trabectedin 6Nivolumab 5pazopanib 4liposomal doxorubicin 3Sunitinib 3Dacarbazine 3pembrolizumab 2eribulin 2durvalumab 2avelumab 2Specimen Handling 2Radiation Dose Hypofractionation 2Letrozole 2Ifosfamide 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1temsirolimus 1sotigalimab 1selinexor 1sargramostim 1rucaparib 1ribociclib 1regorafenib 1pegfilgrastim 1olaratumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leiomyosarcoma × BO-112 × Clear all
NCT04420975 2026-03-10

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
14 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡